Notícias

Trial setback puts focus on Novo Nordisk stock Novo Nordisk (NYSE:NVO) is under fresh scrutiny after the ZEUS phase 3 trial for heart drug candidate ziltivekimab failed to reduce major adverse cardiovascular events versus placebo, prompting a share price drop. See our latest analysis for Novo Nordisk. The ZEUS result comes after a tougher start to the year for Novo Nordisk, with the share price down 10.14% year to date and the latest 1 day move falling 8.78%. However, the 90 day share price...

Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which sets up a different picture from what the share price alone might suggest. Recent headlines around the ZEUS trial setback and legal action against Eli Lilly have sharpened the focus on whether the current price fairly reflects the risks and opportunities. The share price decline of 36.4% over three years points to a period where investors who bought...

The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.

With the stock near a 5-year low, is it worth a look?

Key takeawaysNovo Nordisk’s U. S.

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

European stock markets closed mixed in Friday trading with the Stoxx 600 easing 0.1%, Germany's DAX

Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj

Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.

The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.

Shares fell after a late-stage cardiovascular trial failed to meet its main goal.

Trial enrolled more than 6,300 patients with cardiovascular and kidney disease

Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year.

The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a placebo in a study of more than 6,300 patients

Novo Nordisk shares dropped after the Danish drugmaker said an experimental medicine didn't reduce risk of major adverse cardiovascular events in a late-stage trial. The company's Denmark-listed stock was down nearly 10%, while its American depositary receipts fell about 9% in premarket trading in New York.

Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial.

The stock was down 9.5% after the company’s experimental medicine ziltivekimab didn’t achieve the expected risk reduction for major cardiovascular events.

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]

Earlier this month, the European Commission granted marketing authorisation for Novo Nordisk’s once-daily Wegovy oral pill for obesity across all EU member states, while Crux announced a collaboration with the company to expand affordable, simplified access to authentic anti-obesity medications like Wegovy for US employer health plans. The combination of Europe’s first GLP-1 obesity tablet approval and a new US pharmacy-benefit carve-out could meaningfully influence how widely and...

Novo Nordisk (CPSE:NOVO B) has partnered with Crux to expand access to anti obesity medicines such as Wegovy for employer health plans in the United States. The collaboration focuses on simpler benefit designs and more predictable pricing for employer sponsored coverage. The initiative targets affordability and access barriers for GLP 1 obesity treatments for covered employees and dependents. Novo Nordisk is a major player in obesity care and GLP 1 therapies, and Wegovy is one of its key...

They may profit from the rapidly growing GLP-1 market in very different ways.

The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Will this pharma company become a new leader in the weight loss market?